Malaria is a leading cause of illness and death in the developing world. Thus, the need for an effective vaccine is great. In this phase 1 trial in Burkina Faso, a merozoite surface protein–based vaccine showed some evidence of protection against clinical malaria.
No takes yet. Share an insight, caveat, or question.
Sirima et al. (2011) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: